Brucke Financial Inc. Buys New Position in Johnson & Johnson (NYSE:JNJ)

Brucke Financial Inc. purchased a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 5,342 shares of the company's stock, valued at approximately $813,000.

Other hedge funds have also bought and sold shares of the company. WealthTrak Capital Management LLC bought a new stake in Johnson & Johnson during the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in Johnson & Johnson in the fourth quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth about $32,000. Conquis Financial LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $33,000. Finally, Bernard Wealth Management Corp. bought a new stake in Johnson & Johnson during the 4th quarter valued at $36,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.2%

NYSE:JNJ traded up $0.31 on Tuesday, hitting $153.25. 6,979,932 shares of the stock were exchanged, compared to its average volume of 7,961,247. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The stock has a market capitalization of $368.73 billion, a price-to-earnings ratio of 23.05, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company's 50-day moving average price is $155.05 and its 200 day moving average price is $153.65.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.39%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Royal Bank of Canada restated an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 16th. Finally, Barclays decreased their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.